Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis has agreed to buy Myricx Bio, a small British oncology company, for up to $1.5bn, adding an early-stage but potentially significant technology to a cancer pipeline the industry keeps racing t [...]
FDA approves at-home pap smear alternative device for cervical cancer screening
The Food and Drug Administration has approved a new device called the Teal Wand, which its creator describes as an "at-home vaginal sample self-collection device for cervical cancer screening.&qu [...]
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years
Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the r [...]
Awesome Games Done Quick raises another $2.5 million for a cancer nonprofit
The weeklong speedrunning marathon Awesome Games Done Quick 2025 wrapped up in the wee hours of Sunday morning, and organizers say it managed to pull in a total of $2,556,305 for Prevent Cancer Founda [...]
Stanford researchers will discuss their agentic 'scientists' that are on course to reshape drug discovery at VB Transform 2026
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]
Inside LinkedIn’s generative AI cookbook: How it scaled people search to 1.3 billion users
LinkedIn is launching its new AI-powered people search this week, after what seems like a very long wait for what should have been a natural offering for generative AI.It comes a full three years afte [...]
Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable
Anthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time [...]
Cerebras stock nearly doubles on day one as AI chipmaker hits $100 billion — what it means for AI infrastructure
Cerebras Systems, the Silicon Valley chipmaker that built the world's largest commercial AI processor, erupted onto the Nasdaq on Wednesday, opening at $350 per share — nearly double its $185 I [...]